160 related articles for article (PubMed ID: 29397435)
1. Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.
Cheng KC; Wu YJ; Cheng KH; Cheng KY; Chen KJ; Wu WC; Lee PY; Chang CH
Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1195-1201. PubMed ID: 29397435
[TBL] [Abstract][Full Text] [Related]
2. Proteomic surveillance of putative new autoantigens in thyroid orbitopathy.
Cheng KC; Hung CT; Cheng KY; Chen KJ; Wu WC; Suen JL; Wu YJ; Chang CH
Br J Ophthalmol; 2015 Nov; 99(11):1571-6. PubMed ID: 26034078
[TBL] [Abstract][Full Text] [Related]
3. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
4. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
5. Serum CYR61 Is Associated with Disease Activity in Graves' Orbitopathy.
Woo YJ; Seo Y; Kim JJ; Kim JW; Park Y; Yoon JS
Ocul Immunol Inflamm; 2018; 26(7):1094-1100. PubMed ID: 28548552
[TBL] [Abstract][Full Text] [Related]
6. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
7. Thyroid volume and severity of Graves' orbitopathy.
Profilo MA; Sisti E; Marcocci C; Vitti P; Pinchera A; Nardi M; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Rago T; Marinò M
Thyroid; 2013 Jan; 23(1):97-102. PubMed ID: 23088654
[TBL] [Abstract][Full Text] [Related]
8. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
10. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to the IGF1 receptor in Graves' orbitopathy.
Minich WB; Dehina N; Welsink T; Schwiebert C; Morgenthaler NG; Köhrle J; Eckstein A; Schomburg L
J Clin Endocrinol Metab; 2013 Feb; 98(2):752-60. PubMed ID: 23264397
[TBL] [Abstract][Full Text] [Related]
12. Altered Expression of CXCL13 and Its Chemokine Receptor CXCR5 on B Lymphocytes during Active Graves' Orbitopathy.
Wan S; Lin M; Mao Y; Chen X; Liang D
Curr Eye Res; 2021 Feb; 46(2):210-216. PubMed ID: 32643429
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory Effects of Calprotectin in Graves' Orbitopathy.
Kim JW; Ko J; Kim J; Yoon JS
Ocul Immunol Inflamm; 2020; 28(1):156-163. PubMed ID: 30452877
[No Abstract] [Full Text] [Related]
14. IgG4 as a Biomarker in Graves' Orbitopathy.
Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.
Mysliwiec J; Palyga I; Nikolajuk A; Kowalska A; Gorska M
Endokrynol Pol; 2012; 63(2):92-6. PubMed ID: 22538746
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
17. Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
Clin Endocrinol (Oxf); 2016 Nov; 85(5):805-812. PubMed ID: 27256639
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Effect of Protocatechuic Aldehyde in an In Vitro Model of Graves' Orbitopathy.
Byun JW; Hwang S; Kang CW; Kim JH; Chae MK; Yoon JS; Lee EJ
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4055-62. PubMed ID: 27494347
[TBL] [Abstract][Full Text] [Related]
19. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy.
Salvi M; Bingoye F; Chung F; Wall JR
J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902
[TBL] [Abstract][Full Text] [Related]
20. Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves' disease.
Ohkura T; Taniguchi S; Yamada K; Nishio N; Okamura T; Yoshida A; Kamijou K; Fukata S; Kuma K; Inoue Y; Hisatome I; Senju S; Nishimura Y; Shigemasa C
Biochem Biophys Res Commun; 2004 Aug; 321(2):432-40. PubMed ID: 15358194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
